Back to search

Switzerland· 68001007

Verquvo 10.0 mg, Filmtabletten

A vericiguat product containing vericiguatum, registered in Switzerland by Bayer (Schweiz) AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC C01DX22

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedVerquvo 10.0 mg, FilmtablettenATCC01DX22REGISTER NO.68001007PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Vericiguat is registered in 15 of 19 countries.

Countries holding a registration under ATC C01DX22 (vericiguat), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Vericiguat · ATC C01DX22

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of vericiguat costs, country by country.

Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.

  • Switzerland: $12.83 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Vericiguat · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$12.83
  • ES Spain$9.99
  • IT Italy$9.50
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
vericiguatum
Manufacturer
Bayer (Schweiz) AG
Country
Switzerland (CH)
ATC code
C01DX22
ATC class
Vericiguat
Defined daily dose
10 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680680010075
    Blist 14 Stk
    CHF 54.35

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Vericiguat in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vericiguat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Verquvo
  • Liechtenstein · Verquvo
  • Norway · Verquvo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8b46e036-e223-4695-a3c9-8bc00b520018
GET /v1/drugs/8b46e036-e223-4695-a3c9-8bc00b520018?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "vericiguatum 10 mg",
  "valid_from": "2025-03-01",
  "limitations": "[{\"description\":\"Zur Behandlung erwachsener Patienten mit einer rekompensierten symptomatischen chronischen Herzinsuffizienz der NYHA Klassen II-IV, deren linksventrikuläre Auswurffraktion (LVEF) vor Behandlung mit Verquvo ≤ 40% beträgt und die – trotz vorab optimal eingestellter Basistherapie, die mindestens eine zuvor stabil eingestellte Dosis eines ARNI (Angiotensin-Rezeptorblocker-Neprilysininhibitor), sowie eines Betablockers, eines Mineralokortikoidrezeptorantagonisten (MRA) und eines SGLT2-Inhibitors enthielt -  eine kürzlich aufgetretene Dekompensation hatten, die eine i.v.-Therapie erforderte.<br>\\n<br>\\nZudem kann Verquvo bei erwiesener Intoleranz oder Kontraindikation gegenüber einer Substanzklasse der Basistherapien die bestehende Herzinsuffizienztherapie nach Dekompensation ergänzen.<br>\\n<br>\\nVor Initiierung der Behandlung mit Verquvo muss eine ausreichende Stabilisierung nach kürzlich aufgetretener Dekompensation sichergestellt werden, insbesondere bei Patienten mit stark erhöhten NT-proBNP-Spiegeln. Die klinische Stabilisierung schliesst die Behandlung der Volumenüberladung mittels intensivierter (intravenöser) Diuretika-Therapie und die Optimierung der Behandlung mit anderen Standardtherapeutika für Herzinsuffizienz ein.<br>\\n<br>\\nDie Erstverordnung von Verquvo darf ausschliesslich durch einen Facharzt für Kardiologie erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-03-01\"}]",
  "galenic_form": "Filmtabl 10 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2023-03-01",
  "self_retention_pct": 10
}

See everything about vericiguat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.